Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Did dan

<< Previous

Bullboard Posts

Next >>

Comment by Edcandoon Aug 15, 2021 8:16pm

170 Views

Post# 33707963

RE:RE:RE:Did dan

No not at all actually. Been here since 2018 (maybe even later 2017). I just stopped posting long ago because I'm simply not worried about this play at all. Post history is easy to check (click on name then go to bottom). You'll need to scroll back a bunch of pages but it's there. The fact that you say you've never seen my name answers that I've been here much longer than you? Also the veracity of my message has nothing to do woth how long ive been here lol. I hit the mail on the head .

<< Previous

Bullboard Posts

Next >>

Options trading in a volatile macro environment